{
    "nct_id": "NCT02675959",
    "official_title": "Safety and Efficacy of Prophylactic Defibrotide in Children, Adolescents, and Young Adults With Sickle Cell Disease or Beta Thalassemia Following MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback",
    "inclusion_criteria": "* Disease: Homozygous Hemoglobin S Disease, or Hemoglobin S B0/+ thalassemia, or Hemoglobin SC Disease, or Beta thalassemia intermedia/majora\n* Patients must demonstrate one or more of the following Sickle Cell Disease Complications (or patients in Cohort 2 can meet other high risk criteria instead)\n* Clinically significant neurologic event (stroke) or any neurologic deficit lasting >24 hours that is accompanied by an infarct on cerebral MRI\n* Acute chest syndrome in the preceding two year period prior to enrollment that have failed, been non-compliant or declined hydroxyurea treatment, or prior to chronic RBC transfusion therapy, exchange transfusion or erythrocyte pheresis.\n* Recurrent painful events (at least 3 in the 2 years prior to enrollment or prior to chronic chronic RBC transfusion therapy, exchange transfusion or erythrocyte pheresis).\n* Abnormal TCD study requiring starting on chronic transfusion therapy and/or exchange transfusions.\n* At least one silent infarct lesion on a MRI scan of the head. Or (directly or probably related to SCD)\n* Sickle Cell nephropathy;\n* Splenic sequestration requiring RBC transfusion;\n* Aplastic crisis requiring RBC transfusion;\n* Avascular necrosis of the hip diagnosed by MRI;\n* Two episodes or more of leg ulcerations;\n* Recurrent priapism .\n* Infant dactylitis.\n\n  * OR for Cohort #2 ONLY: Patient must be between 18 and 34.99 years of age, patients must demonstrate at least two of the following:\n* WBC > 13,500 cells/microliter at baseline when not acutely ill (on two separate occasions) > 2 weeks from a VOC event or hospitalization.\n* Tricuspid Regurgitant Jet Velocity (TRV) > 3.0 m/s\n* Requiring Chronic Monthly Transfusions ( > 12 transfusions in the 12 months)\n* History of sepsis\n* N-terminal pro-brain natriuretic peptide (NT-proBNP) > 160 ng/L at clinical baseline when not acutely ill or hospitalized.\n* all patients must meet disease, age, organ function and donor criteria;\nHealthy volunteers allowed\nMust have minimum age of 6 Months\nMust have maximum age of 34 Years",
    "exclusion_criteria": "* Patients who are receiving concomitant systemic anticoagulants and/or fibrinolytic therapies.\n* Patients with a previously known hypersensitivity reaction to defibrotide.\n* Females who are pregnant or breast-feeding are not eligible\n* SCD Patients with documented uncontrolled infection at the time of study entry are not eligible.\n* SCD patients who have an unaffected HLA matched family donor willing to proceed to donation will not be eligible for this study.\n* Karnofsky or Lansky (age appropriate) Performance Score <50% (hemiplegia alone secondary to a previous stroke is not an exclusion)\n* Demonstrated lack of compliance with medical care.\n* Patients with clinically significant fibrosis or cirrhosis of the liver will not be eligible.\n* Patients who have previously received a HSCT will not be eligible.\n* Patients with contraindications to the use of defibrotide",
    "miscellaneous_criteria": ""
}